Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial

AIM: To assess the efficacy and safety of imeglimin monotherapy compared with placebo for 24 weeks in Japanese patients with type 2 diabetes (T2D). MATERIALS AND METHODS: In this 24‐week, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐ranging, phase 2b clinical trial, Japanese ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubourg, Julie, Ueki, Kohjiro, Grouin, Jean‐Marie, Fouqueray, Pascale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898540/
https://www.ncbi.nlm.nih.gov/pubmed/33275318
http://dx.doi.org/10.1111/dom.14285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898540/
https://www.ncbi.nlm.nih.gov/pubmed/33275318
http://dx.doi.org/10.1111/dom.14285

Ejemplares similares